Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Arcus Biosciences Inc (NYSE: RCUS) closed the day trading at $14.84 down -6.49% from the previous closing price of $15.87. In other words, the price has decreased by -$6.49 from its previous closing price. On the day, 0.79 million shares were traded. RCUS stock price reached its highest trading level at $16.04 during the session, while it also had its lowest trading level at $14.79.
Ratios:
For a better understanding of RCUS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.52 and its Current Ratio is at 4.52. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on November 18, 2022, initiated with a Neutral rating and assigned the stock a target price of $33.
On October 11, 2022, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $40.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 27 ’24 when Jarrett Jennifer sold 11,551 shares for $17.55 per share. The transaction valued at 202,720 led to the insider holds 215,253 shares of the business.
Jarrett Jennifer sold 13,449 shares of RCUS for $240,941 on Mar 18 ’24. The Chief Operating Officer now owns 226,804 shares after completing the transaction at $17.92 per share. On Feb 27 ’24, another insider, Jarrett Jennifer, who serves as the Chief Operating Officer of the company, sold 34,070 shares for $20.11 each. As a result, the insider received 685,148 and left with 240,253 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 1348433664 and an Enterprise Value of 710434048. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.52 while its Price-to-Book (P/B) ratio in mrq is 2.43. Its current Enterprise Value per Revenue stands at 6.072 whereas that against EBITDA is -2.14.
Stock Price History:
Over the past 52 weeks, RCUS has reached a high of $25.47, while it has fallen to a 52-week low of $12.95. The 50-Day Moving Average of the stock is -15.23%, while the 200-Day Moving Average is calculated to be -16.48%.
Shares Statistics:
Over the past 3-months, RCUS traded about 847.40K shares per day on average, while over the past 10 days, RCUS traded about 479010 shares per day. A total of 75.50M shares are outstanding, with a floating share count of 47.33M. Insiders hold about 47.91% of the company’s shares, while institutions hold 54.23% stake in the company. Shares short for RCUS as of 1711584000 were 8253290 with a Short Ratio of 9.74, compared to 1709164800 on 7683228. Therefore, it implies a Short% of Shares Outstanding of 8253290 and a Short% of Float of 13.63.
Earnings Estimates
At present, Arcus Biosciences, Inc. analysts are actively evaluating the performance of Arcus Biosciences Inc (RCUS) in the stock market.The consensus estimate for the next quarter is $85.25, with high estimates of $25.14 and low estimates of $18.22.
